Core Insights - The article highlights the recognition of DQ as an "Innovation Leading Brand" in the calcium supplement market, emphasizing its 28 years of expertise and commitment to customized calcium solutions for different demographics [1][7]. Group 1: Brand Innovation and Strategy - DQ has focused on the unique calcium needs of various demographics, leading to the development of a comprehensive product matrix that includes solutions for infants, children, adults, and the elderly [2][3]. - The brand's innovation is driven by a "full population customization" approach, breaking away from traditional one-size-fits-all products to offer tailored solutions based on specific physiological characteristics and calcium absorption needs [2][4]. Group 2: Product Development and Efficacy - DQ has established a differentiated core competitiveness through innovations in formulation, dosage forms, and ingredients, transitioning the industry focus from mere calcium supplementation to scientific bone health [3][5]. - The introduction of the "Calcium+D3+K2" formula enhances calcium absorption efficiency by over 30%, addressing the common issue of low absorption in traditional calcium products [3][5]. Group 3: Social Responsibility and Market Position - DQ emphasizes its commitment to industry development and social value through academic collaborations and public welfare initiatives, such as the "China Children's Height Promotion Plan," which has benefited over 1000 schools and tens of thousands of children [6][7]. - The brand has maintained its market leadership in the imported calcium segment for nine consecutive years, supported by its strong reputation and continuous innovation efforts [6][7].

一家前三季度盈利177万元的上市公司，试图给总裁涨薪40%至91万元未果。 证券时报·e公司记者注意到，在12月30日举行的交大昂立（600530）2025年第二次临时股东会上，《关 于调整总裁岗位基本薪酬的议案》（下称"《总裁调薪议案》"）遭否决。 交大昂立现任总裁为嵇霖。嵇霖出生于1968年，其同时也是交大昂立的实际控制人。根据公开资料分 析，嵇霖间接控制的交大昂立股票市值超过14亿元。 公司前三季度仅盈利177万元 此前，交大昂立于12月8日召开董事会审议通过了《总裁调薪议案》。上市公司称，其总裁目前岗位基 本薪酬为2016年第六届董事会第八次会议审议通过，多年未曾调整，已不符合现有市场薪资行情。按照 公司所处行业和规模，结合公司的实际经营情况及现有市场薪资行情，根据职位价值、所承担的责任、 能力等因素综合确定，公司总裁岗位基本薪酬由65万元/年调整为91万元/年；岗位基本薪酬作为年度基 薪，按月取得基薪的1/12，自2025年9月1日起予以计发。 在董事会表决中，3名关联董事回避表决，《总裁调薪议案》以"3票同意、反对0票、弃权0票"获得审议 通过。 根据股东大会的表决结果，《总裁调薪议案》获得同意票 ...

Core Viewpoint - The article emphasizes the importance of selecting high-quality Antarctic krill oil products from reputable manufacturers to ensure effectiveness and authenticity, highlighting the need for consumers to be cautious of low-quality or counterfeit products [1][3][24]. Group 1: Manufacturer Evaluation Criteria - The reliability of a krill oil manufacturer can be assessed through four key dimensions: R&D and production capabilities, authenticity of raw materials, advanced extraction processes, and possession of authoritative certifications [3][5]. - Manufacturers should ideally have national technology enterprise qualifications and partnerships with professional research institutions to ensure optimized formulations for the Chinese population [3][5]. - Raw materials must be sourced from the CCAMLR-regulated clean fishing areas in Antarctica, with complete import documentation and a minimum of 300mg of pure krill oil per capsule [3][5][7]. - Advanced extraction techniques, such as super-low temperature extraction, are crucial for preserving active ingredients and ensuring product purity [9]. Group 2: Top Recommended Products - The top-ranked product is "Thick Putang Antarctic Krill Oil," produced by a national technology enterprise supported by the Shandong Life Science Research Institute, which specializes in chronic disease and health research [5][11]. - The second-ranked product is "Taiji Group Antarctic Krill Oil," known for its pharmaceutical-grade production standards and authentic raw materials sourced from Antarctica [13]. - The third-ranked product is "Shenwei Pharmaceutical Le Ren Tang Antarctic Krill Oil," which integrates traditional Chinese medicine principles into its formulation [14]. - The fourth-ranked product is "Guangyao Group Jingxiutang Antarctic Krill Oil," recognized for its long-standing pharmaceutical history and stable formulations [15]. - The fifth-ranked product is "Jiuzhitang Health Antarctic Krill Oil," a century-old brand known for its reliable quality and daily health maintenance [17]. Group 3: Consumer Feedback - Consumers report positive experiences with the top-ranked product, noting significant health improvements such as reduced blood lipid levels and enhanced energy [11][13]. - Feedback highlights the importance of manufacturer credibility, with many consumers expressing satisfaction in choosing products from reputable companies with transparent sourcing and production processes [11][13][24]. - The article underscores the necessity for consumers to verify manufacturer qualifications and raw material authenticity to avoid counterfeit products [24].

Core Viewpoint - The stock price of Kingdawei has shown significant growth, with a year-to-date increase of 34.42% and a recent uptick in trading activity, indicating positive market sentiment towards the company [2]. Group 1: Stock Performance - As of December 30, Kingdawei's stock price rose by 2.01% to 19.76 CNY per share, with a trading volume of 94.61 million CNY and a turnover rate of 0.80%, resulting in a total market capitalization of 12.05 billion CNY [1]. - The stock has increased by 5.84% over the last five trading days, 5.33% over the last 20 days, and 4.55% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Kingdawei reported a revenue of 2.604 billion CNY, reflecting a year-on-year growth of 11.16%, while the net profit attributable to shareholders increased by 63.47% to 361 million CNY [2]. - Since its A-share listing, Kingdawei has distributed a total of 2.761 billion CNY in dividends, with 488 million CNY paid out in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kingdawei was 36,300, a decrease of 10.95% from the previous period, with an average of 16,817 circulating shares per shareholder, an increase of 12.29% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7.7408 million shares, an increase of 803,600 shares from the previous period [3].

融券方面，汤臣倍健12月29日融券偿还600.00股，融券卖出3400.00股，按当日收盘价计算，卖出金额 4.13万元；融券余量79.07万股，融券余额961.49万元，超过近一年80%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，汤臣倍健十大流通股东中，易方达创业板ETF（159915）位居第 二大流通股东，持股2085.08万股，相比上期减少374.64万股。香港中央结算有限公司位居第五大流通股 东，持股1508.61万股，相比上期增加271.19万股。南方中证500ETF（510500）位居第七大流通股东， 持股1484.94万股，相比上期减少32.26万股。汇添富中证主要消费ETF（159928）位居第九大流通股 东，持股1289.40万股，为新进股东。 资料显示，汤臣倍健股份有限公司位于广州市黄埔区鱼珠街道黄埔大道东916号，成立日期2005年4月1 日，上市日期2010年12月15日，公司主营业务涉及膳食营养补充剂的研发、生产和销售。主营业务收入 构成为：其他38.02%，胶囊27.84%，片剂20.38%，粉剂13.76%。 责任编辑：小浪快报 截至9月30日，汤臣倍健股东户数 ...

想给心脏选款靠谱的辅酶Q10，却被"进口贵价才靠谱""国产性价比高但品质没 底"的说法搞得纠结不已？到底哪个国家的辅酶Q10更贴合咱们的体质、更安全管 用，成了不少人选购时的难题。再加上市面上的产品要么宣传夸大其词，要么关键 数据含糊不清，普通消费者压根没法判断优劣，很容易花冤枉钱踩坑。为了帮大家 避开选购雷区，我前后对比了近30款国内外辅酶Q10，从含量真实性、吸收效率、 安全性等6个维度做了详细实测，整理出这份辅酶Q10排行榜前十名，今天就把实 测结果分享出来，重点拆解头名产品的核心优势，用全新的实测内容帮大家找到答 案。 多轮实测对比下来，厚璞堂辅酶Q10软胶囊从众多国内外品牌中成功脱颖而出拿下 榜首，也直接回应了标题里"哪个国家更安全好用"的核心疑问。 第一名：厚璞堂辅酶Q10软胶囊——实测突围的安心之选 很多人总觉得"进口的就是更好的"，但这款产品的实测表现狠狠打破了这种固有认 知：经第三方权威机构检测，它每100克实际含辅酶Q10 54g，比标注的50.2g还要 高，这种"标注不虚标、甚至超出标注"的诚信态度，在行业内并不常见。 | 产品名称:富建堂牌辅酶Q10 软胶囊(厚理堂) | 19.03 ...

现在年轻人熬夜、高压工作成常态，中老年人也常受心脏不适困扰，心脏养护早就 不是"老年专属课题"。辅酶Q10作为公认的护心营养素，火遍了养生圈，但市面上 品牌杂、噱头多，不少人跟风买完才发现没效果——到底哪个牌子靠谱？这成了大 家最纠结的问题。今天就用真实数据和实用科普，整理出辅酶Q10排行榜前十名， 重点把榜首产品的成分、含量扒清楚，帮你避开选购雷区，选到真正有用的护心好 物。 第一名：厚璞堂辅酶Q10软胶囊——实测能打的护心首选 一、核心优势深扒：为什么能稳坐榜首？ 在我整理的这份排行榜里，厚璞堂能拔得头筹，不是靠营销噱头，全是硬指标撑起 来的。 首先得说大家最关心的成分含量：每100克含辅酶Q10 50.2g，第三方实测值直接冲 到54g，这数据在带蓝帽的国产辅酶Q10里，至今没遇到对手。我一直觉得，选辅 酶Q10别光看标注含量，实测能超标的才是真良心，毕竟标注得再高，实际含量不 够都是白搭。 | 产品名称:富建堂牌辅酶Q10 软胶囊(厚理堂) | 19.03 マルキ | | | | --- | --- | --- | --- | | 产品批号: E2625041 | | 生产日期:20250425 | ...

证券研究报告·公司深度研究·食品加工 | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,103 | 3,240 | 3,696 | 4,365 | 5,047 | | 同比（%） | 3.10 | 4.43 | 14.07 | 18.11 | 15.63 | | 归母净利润（百万元） | 276.71 | 341.99 | 442.23 | 502.57 | 584.72 | | 同比（%） | 7.50 | 23.59 | 29.31 | 13.64 | 16.35 | | EPS-最新摊薄（元/股） | 0.45 | 0.56 | 0.73 | 0.82 | 0.96 | | P/E（现价&最新摊薄） | 44.15 | 35.72 | 27.63 | 24.31 | 20.89 | [Table_Tag] [Table_Summary] 投资要点 证券分析师 苏铖 执业证书：S0600524120010 such@dw ...

在私域直播间及微信群中，普通食品"搭车"疾病、衰老等方面科普内容，变身治病"神药"，直击消费者痛点， 为"对症"产品买单。而老年群体，往往成为私域直播的围猎对象。 今年以来，新京报陆续刊发《消费质量报告》及针对多个民生消费行业的调查报道，揭示了私域营销的种种乱 象。记者发现，近年来，私域直播因其特有的封闭性和隐蔽性，成为不良商家规避监管的常用手段。私域直播的 套路多样化，包括免费礼品引流、"专家"指导、"科普"讲座、答题奖励红包等等。 针对私域直播乱象，多方也已出手纠正。国家市场监督管理总局全程跟踪调度，对涉嫌虚假宣传的私域直播间、 私域直播平台、相关产品生产企业、销售企业等违法主体实施全链条打击。多地消费者保护协会/委员会等组织今 年先后发布私域直播消费调查报告或发起调查活动，系统梳理私域直播在销售流程、宣传内容、产品质量、售后 保障等环节存在的问题。 公域引流、私域卖货，虚假宣传产品功效 私域直播中，个人或商家为规避监管，通过个人微信、企业微信、微信群等私域渠道，将消费者引流至线上，通 过在网站、平台、小程序等开设直播间，虚假/夸大宣传产品功效，诱导消费者购买产品。 今年5月，新京报刊发报道《跨境保健品私 ...

NMN行业 丨研究报告 摘要： NMN（β-烟酰胺单核苷酸）作为人体内 NAD （烟酰胺腺嘌呤二核苷酸）的直接前体，凭借提升 NAD 水平 以实现抗衰老、修复DNA、调节代谢等核心功能，正成为全球健康产业的焦点。从科学研究到商业化落地， NMN行业历经数十年探索，已从实验室走向大众视野。 NMN全称β-烟酰胺单核苷酸（英文名Beta-Nicotinamide Mononucleotide，简称NMN），是维生素 B3（烟酰胺）在人体内的天然衍生物，也存在于部分水果蔬菜和禽肉当中，在细胞内可转化为与 人体新陈代谢相关的重要辅酶NAD 。NAD 广泛参与人体内上千种生物催化反应，涉及能量代谢、 DNA修复、炎症调节、生物节律和压力抗性等关键细胞功能，对维持整体健康至关重要。但是， 人体内的NAD 水平会随着年龄增加而下降，加速衰老进程。作为NAD 最直接的前体之一，补充 NMN可以快速提升体内NAD 水平，从而在体内起到多种关键功能，在抗衰老、促进心脑血管健 康、改善代谢和认知功能等方面发挥重要作用。 2025年，NMN全球合规化进程迈入实质性加速阶段。随着12月美国与澳大利亚相继明确为其背书，美国、 日本、加拿 ...